Ceterix Orthopaedics receives FDA clearance for meniscal repair system
Ceterix Orthopaedics Inc. announced it received FDA clearance for its NovoStitch Pro Meniscal Repair System, which reportedly offers enhanced technical features to improve the ease of use and workflow for the surgeon.
According to a company press release, the NovoStitch systems allows surgeons to address complex meniscal tears that have not been amenable to repair in the past by enabling surgeons to place stitches arthroscopically in tight joint compartments. The release noted an ergonomic and intuitive handle design, the addition of well-defined visual cues for precise stitch placement, and improved control and stability from upper jaw texturing are enhancements included in the newly FDA-cleared NovoStitch Pro system.
“This FDA clearance is another important milestone in our mission to reduce the number of meniscectomies and to save the meniscus,” John McCutcheon, president and CEO of Ceterix, said in the release. “Ceterix continues to be the leader in meniscal repair by providing innovations that preserve tissue and sustain the natural biomechanics of the knee joint.”